Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory open-label study of SC12267 35 mg in inflammatory bowel disease
2008-005903-25Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vidofludimus calcium in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by 4SC AG. Primary endpoint: Clinical response after 12 weeks. Started Nov 2008; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2008-005903-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005903-25.